Cd62l- tem (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 60 | 再生不良性貧血 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03836690 (ClinicalTrials.gov) | October 21, 2019 | 10/1/2019 | Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation | Phase I Study of Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation | Lymphoma;Leukemia;Myeloma;Myelodysplastic Syndromes;Severe Aplastic Anemia;Primary Immune Deficiency;Graft Vs Host Disease | Biological: CD62L- Tem | University College, London | Medical Research Council | Recruiting | 16 Years | 70 Years | All | 18 | Phase 1 | United Kingdom |